valproic acid has been researched along with Kidney Diseases in 26 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study we compared the effect of two HDAC inhibitors, trichostatin A and valproic acid, in an experimental model of kidney fibrosis." | 7.79 | Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. ( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013) |
| "Renal fibrosis is a common pathological feature of the progression of chronic kidney disease." | 5.46 | Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017) |
| "Mice in the HFD group displayed more severe albuminuria, glomerular hypertrophy, renal oxidative damage, inflammation, and lipid accumulation than mice with the normal diet (ND) group, as well as lower levels of intestinal SCFA valproic acid, colonic inflammation, and tight junction protein downregulation." | 4.31 | ACT001 Alleviates chronic kidney injury induced by a high-fat diet in mice through the GPR43/AMPK pathway. ( Chen, Z; Li, P; Li, Y; Liu, J; Mi, Y; Niu, B; Zhou, H; Zhou, Y, 2023) |
| " In this study we compared the effect of two HDAC inhibitors, trichostatin A and valproic acid, in an experimental model of kidney fibrosis." | 3.79 | Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. ( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013) |
| " In addition, the chemotherapeutic agent ifosfamide caused a decrease in plasma GPx activity in pediatric osteosarcoma patients." | 3.70 | Plasma glutathione peroxidase and its relationship to renal proximal tubule function. ( Avissar, N; Bhamre, S; Cohen, HJ; Ornt, DB; Salvatierra, O; Scandling, JD; Tham, DM; Tune, BM; Whitin, JC, 1998) |
| "Anticonvulsant therapy was among the first areas to benefit from clinical pharmacokinetic studies." | 2.35 | Clinical pharmacokinetics of anticonvulsants. ( Dam, M; Hvidberg, EF, 1976) |
| " This was achieved safely through a reduced dosing schedule of three times a week post dialysis, slow dose titration and blood level monitoring prior to each dialysis session." | 1.62 | Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy. ( Salisbury, E; Topp, S, 2021) |
| "Renal fibrosis is a common pathological feature of the progression of chronic kidney disease." | 1.46 | Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017) |
| " Our data suggest that valproate has adverse effects on renal tubular functions." | 1.42 | Does nephrotoxicity exist in pediatric epileptic patients on valproate or carbamazepine therapy? ( Buyan, N; Demir, E; Gücüyener, K; Gülbahar, Ö; Gürkaş, E; Havali, C; Serdaroğlu, A; Yılmaz, Ü, 2015) |
| " The specificity of acute kidney injury (AKI) biomarkers, iNOS, and nitrotyrosine was evaluated by dosing rats with valproic acid (VPA)." | 1.35 | Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. ( Bonventre, JV; Brown, RP; Espandiari, P; Goering, PL; Hanig, JP; Keenan, J; Kilty, CG; Sadrieh, N; Shaw, M; Vaidya, VS; Zhang, J, 2009) |
| "Although renal Fanconi syndrome resulting from valproate (VPA) has occasionally been reported, the detailed clinical characteristics of this disease remain unclear." | 1.33 | Secondary renal Fanconi syndrome caused by valproate therapy. ( Abe, T; Abe, Y; Watanabe, T; Yamazaki, S; Yoshikawa, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (34.62) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kudose, S | 1 |
| Lipton, M | 1 |
| Jain, NG | 1 |
| D'Agati, VD | 1 |
| Kandemir, FM | 1 |
| Ileriturk, M | 1 |
| Gur, C | 1 |
| Zhou, Y | 1 |
| Chen, Z | 1 |
| Zhou, H | 1 |
| Niu, B | 1 |
| Liu, J | 1 |
| Li, Y | 1 |
| Mi, Y | 1 |
| Li, P | 1 |
| Topp, S | 1 |
| Salisbury, E | 1 |
| Koga, S | 1 |
| Kimata, T | 1 |
| Yamanouchi, S | 1 |
| Tsuji, S | 1 |
| Yoshimura, K | 1 |
| Araki, A | 1 |
| Kaneko, K | 1 |
| Hamed, SA | 1 |
| Rageh, TA | 1 |
| Mohamad, AO | 1 |
| Abou Elnour, SM | 1 |
| Van Beneden, K | 1 |
| Geers, C | 1 |
| Pauwels, M | 1 |
| Mannaerts, I | 1 |
| Wissing, KM | 1 |
| Van den Branden, C | 1 |
| van Grunsven, LA | 1 |
| Havali, C | 1 |
| Gücüyener, K | 1 |
| Buyan, N | 1 |
| Yılmaz, Ü | 1 |
| Gürkaş, E | 1 |
| Gülbahar, Ö | 1 |
| Demir, E | 1 |
| Serdaroğlu, A | 1 |
| Kawaoka, K | 1 |
| Doi, S | 1 |
| Nakashima, A | 1 |
| Yamada, K | 1 |
| Ueno, T | 1 |
| Doi, T | 1 |
| Masaki, T | 1 |
| Zhang, J | 1 |
| Goering, PL | 1 |
| Espandiari, P | 1 |
| Shaw, M | 1 |
| Bonventre, JV | 1 |
| Vaidya, VS | 1 |
| Brown, RP | 1 |
| Keenan, J | 1 |
| Kilty, CG | 1 |
| Sadrieh, N | 1 |
| Hanig, JP | 1 |
| Watanabe, T | 1 |
| Yoshikawa, H | 2 |
| Yamazaki, S | 2 |
| Abe, Y | 1 |
| Abe, T | 1 |
| Ramsay, RE | 1 |
| Bruni, J | 1 |
| Albright, PS | 1 |
| Leroux, M | 1 |
| Budnik, D | 1 |
| Hall, K | 1 |
| Irvine-Meek, J | 1 |
| Otten, N | 1 |
| Seshia, S | 1 |
| Asconapé, JJ | 1 |
| Penry, JK | 1 |
| Ng, JY | 1 |
| Disney, AP | 1 |
| Jones, TE | 1 |
| Purdie, G | 1 |
| Raza, M | 2 |
| Al-Bekairi, AM | 2 |
| Ageel, AM | 1 |
| Qureshi, S | 2 |
| Whitin, JC | 1 |
| Tham, DM | 1 |
| Bhamre, S | 1 |
| Ornt, DB | 1 |
| Scandling, JD | 1 |
| Tune, BM | 1 |
| Salvatierra, O | 1 |
| Avissar, N | 1 |
| Cohen, HJ | 1 |
| Hong, SK | 1 |
| Anestis, DK | 1 |
| Brown, PI | 1 |
| Rankin, GO | 1 |
| al-Shabanah, OA | 1 |
| Verrotti, A | 1 |
| Greco, R | 1 |
| Pascarella, R | 1 |
| Matera, V | 1 |
| Morgese, G | 1 |
| Chiarelli, F | 1 |
| Gugler, R | 1 |
| Mueller, G | 1 |
| Hvidberg, EF | 1 |
| Dam, M | 1 |
| Shirkey, RJ | 1 |
| Jellett, LB | 1 |
| Kappatos, DC | 1 |
| Maling, TJ | 1 |
| Macdonald, A | 1 |
| Warter, JM | 1 |
| Marescaux, C | 1 |
| Hirsch, E | 1 |
| Rumbach, L | 1 |
| Micheletti, G | 1 |
| Chabrier, G | 1 |
| Imler, M | 1 |
3 reviews available for valproic acid and Kidney Diseases
| Article | Year |
|---|---|
The clinical pharmacology of antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Drug Interactions; Ethosuximide; Female; Hal | 1984 |
Use of antiepileptic drugs in the presence of liver and kidney diseases: a review.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Half-Life; Humans; Kidney Diseases; Kinetics; Liver Diseas | 1982 |
Clinical pharmacokinetics of anticonvulsants.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Anticonvulsants; Carbamazepine; Child; Clonazepam | 1976 |
23 other studies available for valproic acid and Kidney Diseases
| Article | Year |
|---|---|
Valproic acid-associated proximal tubulopathy.
Topics: Humans; Kidney Diseases; Kidney Tubules, Proximal; Valproic Acid | 2022 |
Rutin protects rat liver and kidney from sodium valproate-induce damage by attenuating oxidative stress, ER stress, inflammation, apoptosis and autophagy.
Topics: Animals; Apoptosis; Autophagy; Biomarkers; Humans; Inflammation; Kidney; Kidney Diseases; Liver; Oxi | 2022 |
ACT001 Alleviates chronic kidney injury induced by a high-fat diet in mice through the GPR43/AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Female; Inflammation; Kelch-Like ECH-Associa | 2023 |
Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Kidney Diseases; | 2021 |
Risk factors for sodium valproate-induced renal tubular dysfunction.
Topics: Adolescent; Adult; Anticonvulsants; beta 2-Microglobulin; Biomarkers; Carnitine; Chi-Square Distribu | 2018 |
Renal dysfunctions/injury in adult epilepsy patients treated with carbamazepine or valproate.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Creatinine; Cross-Sectional Studies; Epilepsy; Fe | 2018 |
Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis.
Topics: Acetylation; Animals; Doxorubicin; Female; Fibrosis; Glomerulosclerosis, Focal Segmental; Histone De | 2013 |
Does nephrotoxicity exist in pediatric epileptic patients on valproate or carbamazepine therapy?
Topics: Adolescent; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Creatinine; Cystatin C; Epi | 2015 |
Valproic acid attenuates renal fibrosis through the induction of autophagy.
Topics: Actins; Adenine; Animals; Autophagy; Cell Line; Collagen Type I; Cytoprotection; Disease Models, Ani | 2017 |
Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine.
Topics: Animals; Antigens; Cell Adhesion Molecules; Cisplatin; Gentamicins; Immunohistochemistry; Kidney; Ki | 2009 |
Secondary renal Fanconi syndrome caused by valproate therapy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Fanconi Syndrome; Female; Humans; Kidney Disea | 2005 |
Safe readministration of valproate after an episode of hepatotoxicity.
Topics: Adult; Female; Humans; Kidney Diseases; Liver; Valproic Acid | 1983 |
Comparison of gas-liquid chromatography and EMIT assay for serum valproic acid.
Topics: Bilirubin; Chromatography, Gas; Hemolysis; Heparin; Humans; Hyperlipidemias; Immunoenzyme Techniques | 1981 |
Acute pancreatitis and sodium valproate.
Topics: Acute Disease; Adult; Female; Humans; Kidney Diseases; Pancreatitis; Valproic Acid | 1982 |
Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Glutathione; Kidney; Kidney Diseas | 1997 |
Plasma glutathione peroxidase and its relationship to renal proximal tubule function.
Topics: Adult; Animals; Antibodies; Cephaloglycin; Child; Creatinine; Fanconi Syndrome; Glutathione Peroxida | 1998 |
Effect of glucuronidation substrates/inhibitors on N-(3,5-dichlorophenyl)succinimide nephrotoxicity in Fischer 344 rats.
Topics: Animals; Biotransformation; Blood Urea Nitrogen; Camphanes; Clofibric Acid; Drinking; Eating; Eugeno | 1999 |
Pathomorphological changes in mouse liver and kidney during prolonged valproate administration.
Topics: Animals; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Epilepsy; Kidney; Kid | 2000 |
Renal tubular function in patients receiving anticonvulsant therapy: a long-term study.
Topics: Adolescent; Age Factors; Anticonvulsants; Carbamazepine; Child; Epilepsy; Female; Follow-Up Studies; | 2000 |
[Study of nine severely disabled children with hypouricemia].
Topics: Adolescent; Adult; Child; Child, Preschool; Disabled Children; Female; Humans; Infant; Kidney Diseas | 2002 |
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.
Topics: Binding Sites; Blood Proteins; Creatinine; Humans; Kidney Diseases; Protein Binding; Serum Albumin; | 1978 |
Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.
Topics: Adult; Blood Proteins; Erythrocytes; Humans; Kidney Diseases; Kinetics; Liver Diseases; Middle Aged; | 1985 |
Decrease of valproate-induced hyperammonemia in normal subjects by lipid ingestion.
Topics: Ammonia; Dietary Fats; Fatty Acids; Humans; Kidney Diseases; Male; Valproic Acid | 1985 |